GEMSİTABİN'E BAĞLI KUTANOZ TOKSİSİTE GELİŞEN KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİ
Gemsitabin kısmen iyi tolere edilebilen; küçük hücreli dışı akciğer karsinomu, meme, over, pankreas ve baş boyun kanserlerinde yaygın kullanım alanı kazanmış bir ilaçtır. Kemik iliği süpresyonu, bulantı, kusma benzeri semptomlar, alerjik reaksiyonlar gibi sistemik yan etkilerinin yanında yaygın olarak dermatolojik toksisiteler de görülebilir. Alopesi, raş, makülopapüler erüpsiyonlar ve diğer nadir görülen lezyonlar gemsitabin tedavisi sürecinde görülebilmektedir. Çalışmamızda evre 4 akciğer adenokarsinomu tanısıyla, ilk kez gemsitabin içeren ikili kemoterapi aldıktan sonra tüm vücudunda yaygın makülopapüler özellikte döküntüler ortaya çıkan 49 yaşındaki erkek hasta ele alınmıştır.
NON SMALL CELL LUNG CARCINOMA WITH GEMCITABINE INDUCED CUTANEOUS TOXICITY
Gemcitabine is considerably well tolerated agent, that is often used for; non small cell lung carcinoma, breast, over, pancreas and head-neck malignancies. It's likely to have dermatologyical reactions, furthermore it has systemic side effects like pancytopenia, nausea, vomitting, flu-like symptoms and allergic reactions. Alopecia, maculopapullar eruptions, erytematous lesions and other derma- tologycal toxicities can occur during gemcitabine treatment. In our study we investigated a fourty nine year old patient with stage 4 lung adeno- carcinoma, that had diffus maculopapullar lesions after his first time combine chemoterapy with gemcitabine.
___
- 1. Öztürk N, Erbaycu AE, et al. ‹leri ve lokal ileri
evre küçük hücreli d›fl› akci¤er kanserinde
gemsitabin ve karboplatin kombinasyonu.
Türk Onkoloji Dergisi 2008; 23: 72-80.
- 2. Chu CY, Yang CH, Chiu HC. Gemcitabineinduced
acute lipodermatosclerosis-like reaction.
Acta Derm Venereol 2001; 81: 426-8.
- 3. Schwartz BM, Khuntia D, Kennedy, et al.
Gemcitabine-induced radiation recall dermatitis
following whole pelvic radiation therapy
Gynecol Oncol 2003; 91: 421-2.
- 4. Marucci G, Sgarbanti E, et al. Gemcitabineassociated
CD8+ CD30 pseudolymphoma.
Br J Dermatol 2001; 145: 650-2.
- 5. Del pozo J, Marthinez W, et al. Linear immunoglobulin
A bullous dermatosis induced by
gemcitabine. Ann Pharmacother 2001; 35:
891-3.
- 6. Bessis D, Guillot B, et al. Gemcitabineassociated
scleroderma-like changes of the
lower extremities. Am Acad Dermatol 2004;
51: 573-6.
- 7. D’Alessandro V, Errico M, et al. Case report:
acro-necrosis of the upper limbs caused by
gemcitabine therapy. Clin Ter 2003; 154:
207-10.
- 8. Bar-Sela G, Beny A, et al. Gemcitabine–
induced radiation recall dermatitis: Case
report. Tumori 2001; 87: 428-30.
- 9. Burstein H J. Side effects of chemotherapy.
Case 1. Radiation recall dermatitis from
gemcitabine. J Clin Oncol 2000; 18: 693-4.
- 10. Castellano D, Hitt R, et al. Side effects of
chemoterapy. Case 2. Radiation recall reaction
induced by gemcitabine. J Clin Oncol 2000;
18: 695-6.
- 11. Schwartz BM, Khuntia D, et al. Gemcitabineinduced
radiation recall dermatitis following
whole pelvic radiation therapy. Gynecol Oncol
2003; 91: 421-2.
- 12. Fakih MG. Gemcitabine induced rectus abdominus
radiation recall. JOP 2006; 7: 306-10.
- 13. Fogarty G, Ball D, et al. Radiation recall
reaction following gemcitabine. Lung Cancer
2001; 33: 299-302.
- 14. Jeter MD, Janne PA, et al. Gemcitabineinduced
radiation recall. Int J Radiat Oncol
Biol Phys 2002; 53: 394-400.
- 15. Chu CY, Yang CH, et al. Fixed erythrodysaesthesia
plaque due to gemcitabine and epirubicin
treatment. Acta Derm Venereol 2002; 82:
147-8.
- 16. Zustovich F, Pavel P, et al. Erysipeloid skin
toksicity induced by gemcitabine. J Eur Acad
Dermatol Venereol 2006; 20: 757-8.
- 17. Kuku I, Kaya E, et al. Gemcitabine–‹nduced
erysipeloid skin lesions in a patient malignant
mesothelioma. J Eur acad Dermatol
Venereol 2002; 16: 271-2.
- 18. Sommers KR, Kong KM, et al. StevensJohnson
syndrome /toxic epidermal necrolysis
in a patient receiving concurrent radiation
and gemcitabine. Anticancer Drugs 2003;
14: 659-62.